Allergan, Novartis Ag, Bausch & Lomb Incorporated, Santen Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc. are dominating the Global Dry Eye Syndrome Market in 2018

Global Dry Eye Syndrome Market is expected to grow at a substantial CAGR of 6.8% in the forecast period 2019 to 2026. The years considered for study are as mentioned below.

Access Full Report at https://databridgemarketresearch.com/reports/global-dry-eye-syndrome-market

Global dry eye syndrome market is an upcoming market which includes key players and local players. The market is growing to the favourable market scenario. The market has a prominent growth in upcoming years due to rising prevalence of dry eye disease and changing geographical trends.

The market has witness developments in terms of merger and acquisitions or product launches to enhance the product portfolio to meet the rising demand of dry eye syndrome treatment. For instance, In June 2018, Bausch +& Lomb announced the launch of Soothe Xtra Protection (XP) Preservative Free lubricant eye drops by expanding the portfolio of the eye health products to meet the rising demand for the dry eye symptoms relief without the usage of the preservatives. This will help the company to expand its product portfolio in the market.

Allergan dominated the dry eye syndrome market. The other key players existing in the market includes Novartis Ag, Bausch & Lomb Incorporated, Santen Pharmaceutical Co., Ltd., Johnson & Johnson Services, Inc., Prestige Consumer Healthcare, Inc., Akorn, Inc., Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., Novaliq Gmbh, Cardinal Health, Alembic Pharmaceuticals Limited., Cipla Inc., Perrigo Company Plc, Senju Pharmaceutical Co. Ltd., Horus Pharma, Rohto Pharmaceutical Co., Ltd., Visufarma, Hubrx and others.

Allergan:

Allergan headquartered in Dublin, Ireland was incorporated in 2013. The company is focused on development, manufacturing and commercializing branded pharmaceutical, biologic, device, surgical and regenerative medicine products for patients around the world. The company provides Medical Aesthetics, Eye Care, Central Nervous System, and Gastroenterology. The market focus category lies under eye care category.  The company deals into various business categories such as U.S. Specialized Therapeutics, U.S. General Medicine, International and Other. The market focus category lies under U.S. Specialized Therapeutics segment.  The company is continuously engaged in developing the dry eye syndrome treatment drug for instance,

·         In June 2019, Allergan participated at the Jefferies 2019 Healthcare Conference which was held in New York on 6th June. The company is continuously engaged in strategic relationship to enhance the product and service of the Radiology such as, this would help the company to enhance its customer base.

It has its global networks through direct sales representatives and distributors across Globe. The company has various subsidiaries such as ZELTIQ Aesthetics, Inc. (U.S.), Bonti, Inc. (U.S.), Allergan Medical (U.S.), Kythera Biopharmaceuticals, Inc. (U.S.), Oculeve, Inc. (U.S.) among others.

It has its global networks through direct sales representatives and distributors in the Asia-Pacific, Europe, North America and South America Middle East & Africa.

Novartis Ag:

Novartis Ag headquartered in Basel, Switzerland was incorporated in 1996. The company is engaged in the research, development, manufacturing and marketing of healthcare products. The company mainly manages their operation in Cancer, Cardio-Metabolic, Immunology & Dermatology, Neuroscience, Ophthalmology, and Respiratory. The market focus category lies under Ophthalmology. The company is continuously engaged in developing the dry eye syndrome treatment drug for instance-

·         In June 2019, Novartis completed the acquisition of Xiidra from Takeda Pharmaceutical Company Limited. This strategy would help the company to boost their ophthalmic portfolio in the market.

It has its global networks through direct sales representatives and distributors in Americas, Asia-Pacific, Europe / Middle East / Africa.

It operates through its subsidiaries such as Sandoz (Germany), AveXis (U.S.), Endocyte (Indiana), Hexal AG (Germany) and others.

Bausch & Lomb Incorporated:

Bausch & Lomb Incorporated headquartered in New York, U.S. was founded in 1853. The company is focused on offering the widest and finest range of eye health products including contact lenses and lens care products, pharmaceuticals, intraocular lenses and other eye surgery products. The company operates in contact lens care, dry eye products, allergy/redness relief, Rx pharmaceuticals, eye wash, eye vitamins, surgical products, vision accessories, safety and industrial cleaning products, diagnostics. The market focus category lies under dry eye products. The company is continuously engaged in developing the dry eye syndrome treatment drug for instance-

·         In June 2018, Bausch & Lomb announced the launch of Soothe Xtra Protection (XP) Preservative Free lubricant eye drops by expanding the portfolio of the eye health products to meet the rising demand for the dry eye symptoms relief without the usage of the preservatives. This will help the company to expand its product portfolio.

It has its global networks through direct sales representatives and distributors in the North America, South America, Europe, Asia-Pacific, Middle East & Africa.

The company has various subsidiaries such as Bausch & Lomb U.K. Limited (U.K.), Bausch & Lomb Australia Pty Ltd (Australia), Bausch & Lomb Mexico, S.A. de C.V. (Mexico), Bausch & Lomb (Philippines), Inc. (Philippines), Bausch & Lomb Eyecare (India) Private Limited (India) and others.